Skip to search formSkip to main contentSkip to account menu

DTS-201

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin
Purpose: There is a clear clinical need for cytotoxic drugs with a lower systemic toxicity. DTS-201 (CPI-0004Na) is a peptidic… 
2007
2007
Results of a phase I study of DTS-201, a peptidic prodrug of doxorubicin, in patients with solid tumors
2547 Background: DTS-201 is a promising prodrug of doxorubicin (dox) designed to preferentially deliver the parent compound to… 
2007
2007
Results of a first-in-man phase I study assessing the safety and pharmacokinetics of a one hour intravenous infusion of DTS-201 every 3 weeks in patients with advanced or metastatic solid tumors
B76 Introduction : DTS-201 is a doxorubicin prodrug which has shown encouraging results in experimental models in terms of both… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)